B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE